



International Journal of Innovative Research in Science Engineering and Technology (IJIRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)



Impact Factor: 8.699

Volume 14, Issue 3, March 2025

Artificial Intelligence and Data Science in the Diagnosis and Treatment Planning of Cystic Fibrosis

Mr. S. Kumaravel M. Sc, M.Phil, B.Ed., [PhD]

Assistant Professor, Department of Computer Applications, Shree Venkateshwara Arts and Science College, Gobi,
Tamil Nadu, India

ABSTRACT: The pancreas and lungs are among the several organs that are impacted by the hereditary disorder known as cystic fibrosis (CF). The application of artificial intelligence (AI) and data analytics in CF diagnosis and treatment planning is revolutionizing patient care. AI-powered techniques enhance genetic screening, medical imaging, and customized treatment plans, all of which are advantageous to patients. This study discusses the use of AI in CF diagnosis, treatment planning, and possible advancements in AI-driven medicine in the future.


KEYWORDS: Artificial Intelligence, Diagnosis, Treatment Planning, Data Science, Machine Learning, Personalized Medicine, and Cystic Fibrosis

SUMMARY: Cystic fibrosis is a hereditary disorder caused by mutations in the CFTR gene that results in the accumulation of thick mucus in organs such as the lungs and pancreas. A timely and accurate diagnosis is essential to providing effective care. In the past, cystic fibrosis has been diagnosed via genetic testing, medical imaging, and sweat chloride testing. Recent advances in AI and data science have significantly improved diagnostic accuracy, personalized treatment regimens, and predictive analytics for the course of sickness. The potential of AI to transform CF diagnosis and treatment planning is examined in this study.

I. INFORMATION & TECHNIQUES

Cystic Fibrosis Diagnosis:

1. Genetic Testing & AI:
 - o AI systems examine genetic information to accurately identify CFTR mutations.
 - o Newborn screening test sensitivity and specificity are improved by machine learning models.



2. Sweat Test Analysis: AI-based technologies reduce human error and improve diagnostic efficiency by interpreting sweat test chloride levels.
3. Medical Imaging & AI:
 - o To identify early CF-related damage, deep learning algorithms examine lung CT and X-ray images.
 - o Over time, AI-assisted picture analysis enhances illness surveillance.


II. PERSONALIZED MEDICINE AND TREATMENT PLANNING

1. AI in medication Development: By forecasting potent molecules for the treatment of cystic fibrosis, AI speeds up medication discovery.

For instance, the creation of CFTR modulators such as Trikafta (elexacaftor/tezacaftor/ivacaftor) was aided by AI-assisted research.

2. Forecasting Disease Progression: AI models evaluate biomarkers, lung function scores (FEV1), and patient history to forecast the course of cystic fibrosis.
 - o Predictive analytics-based recommendations for individualized treatment.

Cystic Fibrosis



3. AI Wearables & Remote Monitoring:
 - o Smart gadgets keep an eye on respiratory symptoms, oxygen levels, and lung function.
 - o AI allows for prompt intervention by identifying early indicators of lung infections.
4. AI Chatbots & Virtual Assistants:
 - o Chatbots with AI capabilities help CF patients with health management, symptom tracking, and prescription reminders.

III. RESULTS AND DISCUSSION

AI in CF diagnosis and treatment planning has been demonstrated to improve patient care, enable timely interventions, and improve diagnostic accuracy. AI-driven genetic analysis reduces false negatives in newborn screening, while AI-assisted imaging detects lung disease early. Additionally, AI-powered predictive models allow clinicians to customize treatment plans, ensuring better illness control. Patients' quality of life is improved when they follow their treatment programs with the aid of virtual assistants and remote monitoring devices. Data privacy, the reliability of AI models, and integration into healthcare procedures remain concerns despite recent advancements.

IV. FINAL THOUGHTS

By improving diagnosis, streamlining treatment planning, and facilitating proactive disease management, artificial intelligence (AI) and data science are revolutionizing the care of people with cystic fibrosis. More progress is anticipated in the areas of AI-enhanced clinical trials, digital twins for individualized treatment simulations, and AI-driven gene therapy. To fully realize AI's promise in CF, ongoing study and cooperation between medical practitioners and AI experts will be essential.

REFERENCES

1. Guimbellot, J. S., Baines, A., Paynter, A., Heltshe, S. L., VanDalsen, J., Jain, M., Rowe, S. M., Sagel, S. D., & GOAL-e2 Investigators. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation. *Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society*. 2021; 20(2), 213–219. <https://doi.org/10.1016/j.jcf.2020.11.008>.
2. Heltshe, S. L., Rowe, S. M., Skalland, M., Baines, A., Jain, M., & GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement. *American Journal of Respiratory and Critical Care Medicine*. 2018; 197(11), 1483–1486. <https://doi.org/10.1164/rccm.201710-2046LE>.
3. Hughan, K.S., Daley, T., Rayas, M.S., Kelly, A., & Roe, A. Female reproductive health in cystic fibrosis. *Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society*. 2019; 18 Suppl 2, S95–S104. <https://doi.org/10.1016/j.jcf.2019.08.024>.
4. Kartal Öztürk G, Conkar S, Eşki A, Gülen F, Keskinoglu A, Demir E. Evaluation of increased arterial stiffness in pediatric patients with cystic fibrosis by augmentation index and pulse wave velocity analysis. *Pediatric Pulmonology*. 2020; 55(5): 1147–1153. <https://doi.org/10.1002/ppul.24688>.
5. Keogh, R. H., & Stanojevic, S. (2018). A guide to interpreting estimated median age of survival in cystic fibrosis patient registry reports. *Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society*, 17(2), 213–217. <https://doi.org/10.1016/j.jcf.2017.11.014>.



INTERNATIONAL
STANDARD
SERIAL
NUMBER
INDIA



INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

 9940 572 462  6381 907 438  ijirset@gmail.com



www.ijirset.com

Scan to save the contact details